Capucci A, Bassein L, Bracchetti D, Carini G, Maresta A, Magnani B
Eur Heart J. 1983 Mar;4(3):148-54. doi: 10.1093/oxfordjournals.eurheartj.a061434.
A double-blind, cross-over study was performed in 23 consecutive patients with unstable angina at rest in order to compare the efficacy of verapamil (480 mg/day) and propranolol (240 mg/day) in reducing the number of anginal crises and nitroglycerin (NTG) consumption. Twenty patients, 15 men and five women, mean age 59.7 (range 45-68) years completed the study. The mean daily number of attacks was 3.1 in the two-day run-in period and 2.9 in a subsequent two-day placebo period immediately preceding the treatment periods. Propranolol reduced the number of attacks to 1.6 (P less than 0.01 compared to the run-in and placebo periods). Verapamil reduced the crises to 0.2/day (P less than 0.01 compared to the run-in placebo and propranolol periods). The NTG consumption behaved in a similar way. Adverse reactions to verapamil were observed in two patients. Although there are objective difficulties in performing correct trials in these kinds of patients, the results of this study indicate the efficacy of verapamil in preventing anginal pains during the "warm phase' of the unstable form and stress the superiority of this calcium antagonist when compared to propranolol.
对23例静息性不稳定型心绞痛患者进行了一项双盲交叉研究,以比较维拉帕米(480毫克/天)和普萘洛尔(240毫克/天)在减少心绞痛发作次数和硝酸甘油(NTG)用量方面的疗效。20例患者完成了研究,其中15例男性,5例女性,平均年龄59.7岁(范围45 - 68岁)。在为期两天的导入期,平均每日发作次数为3.1次,在紧接着治疗期之前的随后两天安慰剂期,平均每日发作次数为2.9次。普萘洛尔将发作次数减少至1.6次(与导入期和安慰剂期相比,P小于0.01)。维拉帕米将发作次数减少至0.2次/天(与导入期、安慰剂期和普萘洛尔期相比,P小于0.01)。NTG用量的变化情况类似。有2例患者观察到对维拉帕米的不良反应。尽管在这类患者中进行正确试验存在客观困难,但本研究结果表明维拉帕米在预防不稳定型心绞痛“急性期”心绞痛发作方面的疗效,并强调了这种钙拮抗剂与普萘洛尔相比的优越性。